ARTICLE | Company News

Amgen, Genentech deal

July 4, 2005 7:00 AM UTC

DNA will pay AMGN $30 million to cancel the remainder of DNA's obligations under a 2002 deal to manufacture AMGN's Enbrel etanercept, a soluble TNF inhibitor marketed to treat moderate to severe rheumatoid arthritis (RA), juvenile RA, ankylosing spondylitis and moderate to severe plaque psoriasis. ...